Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham.
Donders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, the Netherlands.
JAMA Psychiatry. 2022 Nov 1;79(11):1133-1138. doi: 10.1001/jamapsychiatry.2022.3010.
To make progress toward precision psychiatry, it is crucial to move beyond case-control studies and instead capture individual variations and interpret them in the context of a normal range of biological systems.
To evaluate whether baseline deviations from a normative reference range in subcortical volumes are better predictors of antipsychotic treatment response than raw volumes in patients with first-episode psychosis (FEP) who were naive to antipsychotic medication.
DESIGN, SETTING, AND PARTICIPANTS: In this prospective longitudinal study, patients with first-episode psychosis who were referred from different clinical settings (emergency department, inpatient units, and outpatient clinics) at the University of Alabama at Birmingham were included. A total of 286 patients were screened, 114 consented, 104 enrolled in the treatment trial, and 85 completed the trial. Patients were observed for 16 weeks. Controls were matched by age and sex. Data were collected between June 2016 and July 2021, and data were analyzed from August 2021 to June 2022.
Risperidone on a flexible dosing scheme for 16 weeks. There was an option to switch to aripiprazole for excessive adverse effects.
The main outcome of this study was to evaluate, in patients with FEP who were naive to antipsychotic medication, the association of baseline raw volumes and volume deviations in subcortical brain regions with response to antipsychotic medication. Raw brain volumes or volume deviation changes after treatment were not examined.
Of 190 included participants, 111 (58.4%) were male, and the mean (SD) age was 23.7 (5.5) years. Volumes and deviations were quantified in 98 patients with FEP, and data from 92 controls were used as comparison for case-control contrasts and reference curve calibration. In case-control contrasts, patients with FEP had lower raw thalamus (P = .002; F = 9.63; df = 1), hippocampus (P = .009; F = 17.23; df = 1), amygdala (P = .01; F = 6.55; df = 1), ventral diencephalon (P = .03; F = 4.84; df = 1), and brainstem volumes (P = .004; F = 8.39; df = 1). Of 98 patients, 36 patients with FEP (36%) displayed extreme deviations. Associations with treatment response significantly differed between raw volume and deviation measures in the caudate (z = -2.17; P = .03) and putamen (z = -2.15; P = .03).
These data suggest that normative modeling allows capture of interindividual heterogeneity of regional brain volumes in patients with FEP and characterize structural pathology in a clinically relevant fashion. This holds promise for progress in precision medicine in psychiatry, where group-level studies have failed to derive reliable maps of structural pathology.
要实现精准精神病学的进展,超越病例对照研究并捕捉个体差异,并在正常的生物系统范围内进行解释至关重要。
评估在首次发作精神病(FEP)患者中,亚皮质体积的基线参考范围偏差是否比原始体积更好地预测抗精神病药物治疗反应,这些患者对抗精神病药物治疗是初治的。
设计、设置和参与者:在这项前瞻性纵向研究中,纳入了来自阿拉巴马大学伯明翰分校不同临床环境(急诊室、住院病房和门诊诊所)的首次发作精神病患者。共筛选了 286 名患者,114 名同意参加,104 名参加了治疗试验,85 名完成了试验。患者观察了 16 周。对照按年龄和性别匹配。数据收集于 2016 年 6 月至 2021 年 7 月,数据分析于 2021 年 8 月至 2022 年 6 月进行。
利培酮的灵活剂量方案治疗 16 周。对于不良反应过多的患者,可以选择改用阿立哌唑。
本研究的主要结果是评估在首次发作精神病且对抗精神病药物初治的患者中,亚皮质脑区的基线原始体积和体积偏差与抗精神病药物治疗反应的相关性。未检查治疗后大脑体积的原始变化或体积偏差。
在 190 名纳入的参与者中,111 名(58.4%)为男性,平均(SD)年龄为 23.7(5.5)岁。在 98 名 FEP 患者中进行了体积和偏差的量化,使用 92 名对照的数据进行病例对照对比和参考曲线校准。在病例对照对比中,FEP 患者的丘脑(P = .002;F = 9.63;df = 1)、海马体(P = .009;F = 17.23;df = 1)、杏仁核(P = .01;F = 6.55;df = 1)、腹侧间脑(P = .03;F = 4.84;df = 1)和脑干体积(P = .004;F = 8.39;df = 1)较低。在 98 名患者中,36 名 FEP 患者(36%)显示出极端偏差。尾状核(z = -2.17;P = .03)和壳核(z = -2.15;P = .03)的原始体积和偏差测量与治疗反应的相关性显著不同。
这些数据表明,规范建模允许在首次发作精神病患者中捕捉到区域脑体积的个体间异质性,并以临床相关的方式描述结构病理学。这有望在精神病学精准医学方面取得进展,因为基于群体的研究未能得出可靠的结构病理学图谱。